CR6964A - Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasa - Google Patents
Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasaInfo
- Publication number
- CR6964A CR6964A CR6964A CR6964A CR6964A CR 6964 A CR6964 A CR 6964A CR 6964 A CR6964 A CR 6964A CR 6964 A CR6964 A CR 6964A CR 6964 A CR6964 A CR 6964A
- Authority
- CR
- Costa Rica
- Prior art keywords
- diabetic
- prodrug
- combinations
- einhibitors
- deshidrogenasa
- Prior art date
Links
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 abstract 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 abstract 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 201000009101 diabetic angiopathy Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a composiciones farmaceuticas que comprenden combinaciones de un agonista de GABA un profarmaco del mismo o una sal farmaceuticamente aceptable de dicho agonista de GABA o dicho profarmaco y un SDI, un profarmaco del mismo o una sal farmaceuticamente aceptable de dicho SDI o dicho profarmaco, estuches que contienen tales combinaciones y metodos para utilizar tales combinaciones en el tratamiento de mamiferos, incluidos los seres humanos, que, padecen complicaciones de la diabetes tales como neuropatia diabetica, nefropatia diabetica, cardiomiopatia diabetica, retinopatia diabetica, microangiopatia diabetica, macroangiopatia diabetica, caratas o ulceras en los pies.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25006900P | 2000-11-30 | 2000-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR6964A true CR6964A (es) | 2004-02-02 |
Family
ID=22946187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR6964A CR6964A (es) | 2000-11-30 | 2003-04-24 | Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasa |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6544998B2 (es) |
| EP (1) | EP1337271B1 (es) |
| JP (1) | JP2004514699A (es) |
| KR (1) | KR20030059290A (es) |
| CN (1) | CN1477975A (es) |
| AP (1) | AP2001002360A0 (es) |
| AR (1) | AR031431A1 (es) |
| AT (1) | ATE281181T1 (es) |
| AU (1) | AU2002215159A1 (es) |
| BG (1) | BG107774A (es) |
| BR (1) | BR0115783A (es) |
| CA (1) | CA2430298A1 (es) |
| CR (1) | CR6964A (es) |
| CZ (1) | CZ20031399A3 (es) |
| DE (1) | DE60106968T2 (es) |
| DO (1) | DOP2001000289A (es) |
| EA (1) | EA200300432A1 (es) |
| EC (1) | ECSP034624A (es) |
| EE (1) | EE200300248A (es) |
| ES (1) | ES2230378T3 (es) |
| HR (1) | HRP20030420A2 (es) |
| HU (1) | HUP0302160A3 (es) |
| IL (1) | IL155704A0 (es) |
| IS (1) | IS6786A (es) |
| MA (1) | MA26964A1 (es) |
| MX (1) | MXPA03004870A (es) |
| NO (1) | NO20032441L (es) |
| OA (1) | OA12534A (es) |
| PA (1) | PA8534101A1 (es) |
| PE (1) | PE20020597A1 (es) |
| PL (1) | PL365927A1 (es) |
| PT (1) | PT1337271E (es) |
| SK (1) | SK6192003A3 (es) |
| SV (1) | SV2003000751A (es) |
| TN (1) | TNSN01169A1 (es) |
| UY (1) | UY27042A1 (es) |
| WO (1) | WO2002043762A2 (es) |
| ZA (1) | ZA200303381B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100491282B1 (ko) | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| US7022678B2 (en) * | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| MXPA03009392A (es) * | 2001-05-25 | 2004-01-29 | Warner Lambert Co | Composicion famaceutica liquida. |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20050036195A (ko) * | 2003-10-15 | 2005-04-20 | 고재영 | 신규한 망막병증 치료제 조성물 |
| US20050220873A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
| KR20070020022A (ko) * | 2004-04-02 | 2007-02-16 | 임팩스 라보라토리즈, 인코포레이티드 | Ｇａｂａ 수용체 효능제에 대한 제어 방출 제형 |
| US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
| US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| KR101063663B1 (ko) | 2005-02-17 | 2011-09-07 | 아스텔라스세이야쿠 가부시키가이샤 | 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 |
| GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
| TWI362930B (en) | 2007-04-27 | 2012-05-01 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
| ES2416723T3 (es) * | 2007-10-09 | 2013-08-02 | Merck Patent Gmbh | Composiciones farmacéuticas que contienen benfotiamina y gabapentina |
| EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
| JP5815552B2 (ja) | 2009-12-08 | 2015-11-17 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 眼疾患を治療する化合物および方法 |
| CN107050456B (zh) * | 2010-09-28 | 2022-08-12 | 加利福尼亚大学董事会 | 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合 |
| KR101589837B1 (ko) | 2011-06-22 | 2016-01-29 | 퍼듀 퍼머 엘피 | 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12433904B2 (en) | 2019-04-17 | 2025-10-07 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| CA3136100A1 (en) * | 2019-05-07 | 2020-11-12 | Stephan L. ZUCHNER | Treatment and detection of inherited neuropathies and associated disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2409754A (en) | 1946-10-22 | Method for obtaining hydantoins | ||
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| CH427803A (de) | 1963-12-06 | 1967-01-15 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Isoxazolderivates |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
| FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
| JPS5625169A (en) | 1979-06-01 | 1981-03-10 | Wellcome Found | Triazine derivative |
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| DK288385D0 (da) | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| KR950703539A (ko) * | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) |
| US6350769B1 (en) * | 1999-02-24 | 2002-02-26 | The Regents Of The University Of California | Gaba alpha receptors mediate inhibition of T cell responses |
| ATE264311T1 (de) * | 1999-04-01 | 2004-04-15 | Pfizer Prod Inc | Verbindungen zur behandlung und vorsorge bei diabetes |
| AU768720B2 (en) * | 1999-04-01 | 2004-01-08 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
-
2001
- 2001-11-19 PL PL01365927A patent/PL365927A1/xx not_active Application Discontinuation
- 2001-11-19 HR HR20030420A patent/HRP20030420A2/hr not_active Application Discontinuation
- 2001-11-19 AP APAP/P/2001/002360A patent/AP2001002360A0/en unknown
- 2001-11-19 IL IL15570401A patent/IL155704A0/xx unknown
- 2001-11-19 CN CNA018195946A patent/CN1477975A/zh active Pending
- 2001-11-19 AT AT01983739T patent/ATE281181T1/de not_active IP Right Cessation
- 2001-11-19 DO DO2001000289A patent/DOP2001000289A/es unknown
- 2001-11-19 CZ CZ20031399A patent/CZ20031399A3/cs unknown
- 2001-11-19 EP EP01983739A patent/EP1337271B1/en not_active Expired - Lifetime
- 2001-11-19 CA CA002430298A patent/CA2430298A1/en not_active Abandoned
- 2001-11-19 HU HU0302160A patent/HUP0302160A3/hu unknown
- 2001-11-19 AU AU2002215159A patent/AU2002215159A1/en not_active Abandoned
- 2001-11-19 WO PCT/IB2001/002213 patent/WO2002043762A2/en not_active Ceased
- 2001-11-19 OA OA1200300142A patent/OA12534A/en unknown
- 2001-11-19 KR KR10-2003-7007237A patent/KR20030059290A/ko not_active Ceased
- 2001-11-19 EE EEP200300248A patent/EE200300248A/xx unknown
- 2001-11-19 DE DE60106968T patent/DE60106968T2/de not_active Expired - Fee Related
- 2001-11-19 SK SK619-2003A patent/SK6192003A3/sk unknown
- 2001-11-19 MX MXPA03004870A patent/MXPA03004870A/es unknown
- 2001-11-19 PT PT01983739T patent/PT1337271E/pt unknown
- 2001-11-19 EA EA200300432A patent/EA200300432A1/ru unknown
- 2001-11-19 JP JP2002545732A patent/JP2004514699A/ja not_active Withdrawn
- 2001-11-19 ES ES01983739T patent/ES2230378T3/es not_active Expired - Lifetime
- 2001-11-19 BR BR0115783-3A patent/BR0115783A/pt not_active IP Right Cessation
- 2001-11-27 UY UY27042A patent/UY27042A1/es not_active Application Discontinuation
- 2001-11-28 PE PE2001001191A patent/PE20020597A1/es not_active Application Discontinuation
- 2001-11-28 AR ARP010105541A patent/AR031431A1/es unknown
- 2001-11-29 US US09/997,038 patent/US6544998B2/en not_active Expired - Fee Related
- 2001-11-29 SV SV2001000751A patent/SV2003000751A/es unknown
- 2001-11-29 TN TNTNSN01169A patent/TNSN01169A1/fr unknown
- 2001-11-30 PA PA20018534101A patent/PA8534101A1/es unknown
-
2003
- 2003-04-14 IS IS6786A patent/IS6786A/is unknown
- 2003-04-24 CR CR6964A patent/CR6964A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303381A patent/ZA200303381B/en unknown
- 2003-05-07 BG BG107774A patent/BG107774A/xx unknown
- 2003-05-20 MA MA27165A patent/MA26964A1/fr unknown
- 2003-05-27 EC EC2003004624A patent/ECSP034624A/es unknown
- 2003-05-28 NO NO20032441A patent/NO20032441L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR6964A (es) | Combinacion de agonistas de gaba einhibidores de sorbitol-deshidrogenasa | |
| AR031432A1 (es) | Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa | |
| AR067347A1 (es) | Combinacion antihelmintica | |
| MX2021004999A (es) | Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos. | |
| ECSP23095307A (es) | Agonista del receptor de glp-1 y composición y uso del mismo | |
| AR025329A1 (es) | Tratamiento medicamentoso del sindrome de piernas inquietas | |
| AR051969A1 (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central | |
| CR8146A (es) | Metodos para tratar canceres usando formas poliformicas de 3-(4-amino -1-oxo-1,3 dihidro-isoindol-2-il)- piperidina-2,6-dione | |
| CL2008002227A1 (es) | Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad. | |
| ECSP10010684A (es) | Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad. | |
| CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
| GT200500173A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
| CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
| DOP2012000132A (es) | Composicion farmaceutica que comprende un agonista de glp-1 y metionina | |
| AR067903A1 (es) | Metodo para tratar la depresion mediada por estres | |
| CL2008003576A1 (es) | Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria. | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| ATE348630T1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
| PA8515601A1 (es) | El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos | |
| ES2581331T3 (es) | Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática | |
| AR033596A1 (es) | Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno | |
| ES2325291A1 (es) | "uso de un extracto de silybum marianum" | |
| AR043016A2 (es) | Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene | |
| AR029557A1 (es) | Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis | |
| ES2477877T3 (es) | Uso de 25-hidroxi vitamina D3 para incrementar la masa muscular en mamíferos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |